LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed.
Help employers find you! Check out all the jobs and post your resume.
